Rituximab: A review of dermatological applications

Journal of Clinical and Aesthetic Dermatology

Volumn 2, Issue 5, 2009, Pages 29-37

  Emer, Jason J ^a   Wolinsky, Claire ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; DIPHENHYDRAMINE; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOGLOBULIN E ANTIBODY; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; PREDNISONE; RAPAMYCIN; RITUXIMAB; T LYMPHOCYTE ANTIBODY; THALIDOMIDE; TUMOR NECROSIS FACTOR ANTIBODY;

ANAPHYLAXIS; ARTICLE; ATOPIC DERMATITIS; AUTOIMMUNE SKIN DISEASE; BULLOUS PEMPHIGOID; CHILL; CYTOPENIA; DERMATOMYOSITIS; DIGESTIVE SYSTEM PERFORATION; DISEASE ACTIVITY; DISEASE CONTROL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EPIDERMOLYSIS BULLOSA ACQUISITA; FEVER; FOLLOW UP; GASTROINTESTINAL OBSTRUCTION; GRAFT VERSUS HOST REACTION; HEADACHE; HEART ARRHYTHMIA; HEMOLYTIC ANEMIA; HEPATITIS B; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFUSION REACTION; KIDNEY FAILURE; LUNG DISEASE; MONOTHERAPY; MUCOUS MEMBRANE PEMPHIGOID; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHODGKIN LYMPHOMA; OFF LABEL DRUG USE; PEMPHIGUS VULGARIS; PNEUMONIA; PRIMARY CUTANEOUS B CELL LYMPHOMA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; RASH; REMISSION; RHEUMATOID ARTHRITIS; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC THERAPY; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; VASCULITIS; VIRUS REACTIVATION; WEAKNESS;

EID: 77954296068     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83(2):435-445.
2. Arin MJ, Engert A, Krieg T, Hunzelmann N. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol. 2005;153(3):620-625.
3. Hertl M, Zillikens D, Borradori L, et al. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges. 2008;6(5):366-373.
4. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs. 2003;63(8):803-843.
5. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005;31(6):456-473.
6. Johnson PW, Glennie MJ. Rituximab: mechanisms and applications. Br J Cancer. 2001;85(11):1619-1623.
7. Esposito M, Capriotti E, Giunta A, et al. Long-lasting remission of pemphigus vulgaris treated with rituximab. Acta Derm Venereol. 2006;86(1):87-89.
8. Schmidt E, Hunzelmann N, Zillikens D, et al. Rituximab in refractory autoimmune bullous diseases. Clin Exp Dermatol. 2006;31(4):503-508.
9. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood. 1994;84(8):2457-2466.
10. Solal-Céligny P. Safety of rituximab maintenance therapy in follicular lymphomas. Leuk Res. 2006;30(Suppl 1):S16-S21.
11. Vidal L, Gafter-Gvili A, Leibovici L, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst. 2009;101(4):248-255.
12. Marcus R. Use of rituximab in patients with follicular lymphoma. Clin Oncol (R Coll Radiol). 2007;19(1):38-49.
13. Gürcan HM, Keskin DB, Stern JN, et al. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol. 2009;9(1):10-25.
14. Higashida J, Wun T, Schmidt S, et al. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment. J Rheumatol. 2005;32 (11):2109-2115.
15. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25): 2572-2581.
16. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete